Spero Therapeutics (SPRO) Debt to Equity (2016 - 2024)
Historic Debt to Equity for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2024 value amounting to $0.0.
- Spero Therapeutics' Debt to Equity fell 8280.99% to $0.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $0.0, marking a year-over-year decrease of 8280.99%. This contributed to the annual value of $0.0 for FY2023, which is 3562.3% down from last year.
- Latest data reveals that Spero Therapeutics reported Debt to Equity of $0.0 as of Q3 2024, which was down 8280.99% from $0.0 recorded in Q2 2024.
- In the past 5 years, Spero Therapeutics' Debt to Equity registered a high of $0.02 during Q1 2022, and its lowest value of $0.0 during Q3 2024.
- Moreover, its 5-year median value for Debt to Equity was $0.0 (2020), whereas its average is $0.0.
- In the last 5 years, Spero Therapeutics' Debt to Equity skyrocketed by 117163.56% in 2022 and then crashed by 9270.72% in 2023.
- Over the past 5 years, Spero Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2020, then rose by 16.6% to $0.0 in 2021, then fell by 19.12% to $0.0 in 2022, then tumbled by 35.62% to $0.0 in 2023, then plummeted by 75.62% to $0.0 in 2024.
- Its Debt to Equity stands at $0.0 for Q3 2024, versus $0.0 for Q2 2024 and $0.0 for Q1 2024.